Article Archive: Karen Andersen, CFA

Title Collection Author Date
Biogen: Earnings Beat Expectations, Maintaining Current Fair Value Estimate Commentary Karen Andersen, CFA 07/21/16
Biogen Remains Undervalued Stock Strategist Karen Andersen, CFA 06/17/16
This Healthy Drugmaker Is Undervalued US Videos Karen Andersen, CFA 06/01/16
Market Underestimating Alzheimer’s R&D US Videos Karen Andersen, CFA 12/16/15
Amgen's Innovation Counters Biosimilar Pressure Stock Strategist Karen Andersen, CFA 10/19/15
The Biosimilar Threat: Which Companies Are at Risk? US Videos Karen Andersen, CFA 08/27/15
Biogen's Drop Looks Like Overreaction Stock Strategist Karen Andersen, CFA 07/27/15
Competition Rising for Baxalta Stock Strategist Karen Andersen, CFA 07/06/15
Roche Builds a Wide Moat With Dominant Oncology and Diagnostics Franchises Stock Strategist Karen Andersen, CFA 06/08/15
Baxter's Spin-Off Strategy Is Promising US Videos Karen Andersen, CFA 05/27/15
Amgen Shares Still Look Undervalued Commentary Karen Andersen, CFA 04/22/15
Morningstar's 2014 CEO of the Year Stock Strategist Karen Andersen, CFA 01/21/15
A Discounted Wide Moat in Biotech US Videos Karen Andersen, CFA 01/21/15
Moats and Growth Drivers Look Solid for Post-Split Baxter Stock Strategist Karen Andersen, CFA 06/15/14
This Undervalued Stock Is a Global Leader US Videos Karen Andersen, CFA 05/07/14
Strong Pipeline Helps Protect Baxter's Wide Moat From Competition Stock Strategist Karen Andersen, CFA 12/30/13
Top Biotech Acquisition Candidates US Videos Karen Andersen, CFA 04/05/12
Drugmakers Delving Into Multiple Sclerosis Market Stock Strategist Industry Reports Karen Andersen, CFA 05/18/11
Our Top Five Biotech Acquisition Candidates US Videos Karen Andersen, CFA 03/17/11
Our Top Five Biotech Takeout Picks US Videos Karen Andersen, CFA 02/26/10
Which Biotechs Are Vulnerable to Generics? Stock Strategist Industry Reports Karen Andersen, CFA 08/03/09
Generic Biologics Face Uphill Battle US Videos Karen Andersen, CFA 08/03/09
Generic Biologics Face Uphill Battle -- Part 2 US Videos Karen Andersen, CFA 08/03/09
Betting on Biotech: The Mispriced and Fiscally Fit Stock Strategist Industry Reports Karen Andersen, CFA 10/13/08
Betting on Biotech: The Mispriced and Fiscally Fit Stock Strategist Karen Andersen, CFA 10/13/08
Spreading Out Your Biotech Risk Sustainability Matters Karen Andersen, CFA 03/24/08
2008 Investing Dos and Don'ts Stock Strategist Karen Andersen, CFA 01/02/08
Why a 3-Star Stock Can Shine with Options Sustainability Matters Karen Andersen, CFA 10/16/07
Does This ETF Exceed the Sum of Its Parts? Fund Spy Karen Andersen, CFA 09/11/07
Upside Exposure Is on Sale for This Biotech Sustainability Matters Karen Andersen, CFA 09/05/07
Five Firms Big Pharma Should Buy Next Stock Strategist Karen Andersen, CFA 04/25/07
Emerging Value in Three Health-Care Stocks? Stock Strategist Karen Andersen, CFA 01/31/07
Is Amgen Ready for a Dividend? Stock Strategist Karen Andersen, CFA 01/08/07
Democrat-Proof Health-Care Stocks Stock Strategist Karen Andersen, CFA 12/01/06
Biotech Investing for the Long Haul Stock Strategist Karen Andersen, CFA 02/22/06